NASDAQ:FEMY Femasys Q1 2026 Earnings Report $3.23 +0.44 (+15.77%) As of 01:40 PM Eastern ProfileEarnings HistoryForecast Femasys EPS ResultsActual EPS$0.10Consensus EPS -$1.33Beat/MissBeat by +$1.43One Year Ago EPSN/AFemasys Revenue ResultsActual Revenue$0.42 millionExpected Revenue$0.77 millionBeat/MissMissed by -$342.11 thousandYoY Revenue GrowthN/AFemasys Announcement DetailsQuarterQ1 2026Date5/8/2026TimeBefore Market OpensConference Call DateFriday, May 8, 2026Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Femasys Earnings HeadlinesFemasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care LocationsAugust 26 at 9:00 AM | globenewswire.comFemasys (NASDAQ:FEMY) Downgraded to Sell Rating by Wall Street ZenAugust 22, 2026 | americanbankingnews.comATTENTION: We just released a new “must-see” exposé on your retirementWeiss Ratings, the watchdog that has flagged major financial shifts for 55 years, is warning about a little-known government financial operation affecting retirement accounts. Its stock ratings have historically produced returns that could have more than tripled the S&P 500's gains since 2003, a track record now focused on this emerging risk.August 28 at 1:00 AM | Weiss Ratings (Ad)Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®August 20, 2026 | markets.businessinsider.comFemasys Secures FDA Approval for Modular PMA Pathway for FemBlocAugust 20, 2026 | finance.yahoo.comFEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside PotentialAugust 20, 2026 | msn.comSee More Femasys Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Femasys? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Femasys and other key companies, straight to your email. Email Address About FemasysFemasys (NASDAQ:FEMY) International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care. The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools. Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.View Femasys ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After EarningsNutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes ShapeCrowdStrike’s “Mythos Moment” Tests the Bigger AI Security TradeIntuit’s Earnings Reset May Be More Pivot Than PlungeOkta Stock Surges 29%—Is $200 the Next Stop?Salesforce Turns the Corner as AI Fears Start to FadeNVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is Upcoming Earnings Medtronic (9/1/2026)Dell Technologies (9/1/2026)Palo Alto Networks (9/1/2026)Broadcom (9/2/2026)Hewlett Packard Enterprise (9/2/2026)Snowflake (9/2/2026)Ciena (9/3/2026)Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
